TAT-11: Astatine-211: The Chemistry Infrastructure

Ottawa, ON, Canada (UroToday.com) Despite the availability of At211 production via Bi209(alpha, 2n)At211 at cyclotrons, alpha therapy research suffers from the lack of a chemical infrastructure for producing an end-product At211-conjugated ligand. Dr. Lindegren described such an automated infrastructure developed at Gothenburg. He also described a clinical trial for treating ovarian cancer with 200 MBq of At211.


Presented by: Sture Lindegren, PhD, Department of Radiation Physics, Gothenburg University, Göteborg, Vaestra Goetaland, Sweden

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe